Aflibercept
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Aflibercept and local guidelines before prescribing.
Mechanism
VEGF trap given by intravitreal injection.
Uses
Neovascular age-related macular degeneration, diabetic macular oedema, retinal vein occlusion.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Eye pain, conjunctival haemorrhage, raised intraocular pressure, endophthalmitis (rare).
Interactions
None significant systemically.
Contraindications and cautions
Active ocular infection
Monitoring
Visual acuity, intraocular pressure
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Intravitreal injection by ophthalmology; report eye pain or visual loss promptly.
More from the textbook: uses, cautions and other points
- Diabetic macular oedema - intravitreal anti-VEGF (aflibercept, ranibizumab, faricimab) first line; dexamethasone or fluocinolone implants; focal laser.
Ophthalmology: Retinal Visual Loss - Macular oedema: Intravitreal anti-VEGF (e.g. aflibercept, ranibizumab, faricimab), steroid implants or laser.
Endocrinology: Diabetes - Macular oedema - intravitreal anti-VEGF injections (ranibizumab, aflibercept, faricimab) or a dexamethasone implant .
Ophthalmology: Retinal Visual Loss - Aflibercept , ranibizumab (including biosimilars), faricimab (also blocks angiopoietin-2), and others.
Ophthalmology: Retinal Visual Loss - Aflibercept / ranibizumab / faricimab (intravitreal) | Anti-VEGF for wet AMD, diabetic macular oedema and vein occlusion oedema; repeated injections; endophthalmitis risk.
Ophthalmology: Retinal Visual Loss - -cept - receptor–Fc fusion protein (etanercept, abatacept, aflibercept).
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology